drugset / Trial / NCT01765829

Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis

NCT01765829 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess if patients who continue with antipsychotic treatment for 12 or more months show the same risk of relapse (measured by PANSS) that patients with the same medical condition who have followed a discontinuation treatment scheme based in the presence of prodromes. The candidates should accomplish the following criteria: first episode of non-affective psychosis who have followed antipsychotic treatment for 12 months and who have already shown remission criteria.

Timeline

Start
2012-11
Primary completion
2015-11
Completion
2015-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Amisulpride Small molecule — —
Subject Aripiprazole Other / unclassified — —
Subject Asenapine Other / unclassified — —
Subject CLOTHIAPINE Small molecule — —
Subject Chlorpromazine Small molecule — —
Subject Clozapine Other / unclassified — —
Subject Droperidol Small molecule — —
Subject Flufenazine Unknown — —
Subject Flupentixol Unknown — —
Subject Haloperidol Other / unclassified — —
Subject Levomepromazine Small molecule — —
Subject Olanzapine Small molecule — —
Subject Paliperidone Unknown — —
Subject Perfenazine Unknown — —
Subject Periciazine Small molecule — —
Subject Pimozide Small molecule — —
Subject Pipotiazine palmitate Small molecule — —
Subject Quetiapine Small molecule — —
Subject Risperidone Other / unclassified — —
Subject Sertindole Small molecule — —
Subject Sulpiride Small molecule — —
Subject Tiapride Small molecule — —
Subject Trifluoperazine Small molecule — —
Subject Ziprasidone Small molecule — —
Subject Zuclopenthixol Unknown — —

Indications